Medical researchers are arming themselves with a new series of weapons in the war against diseases – conjugated drugs that link biological molecules to a highly potent active pharmaceutical ingredient (HPAPIs). Cynthia Wooge, SAFC® process development manager and a leading expert on conjugation technology gives us an overview of this new exciting technology where we could see some projects reach commercial scale within the next 1-4 years. Dr Wooge also discusses details of the current industry guidance about safely handling highly potent APIs.
Access to all documents and request for further information are available to all users at no cost. In order to provide you with this free service, William Reed Business Media SAS does share your information with companies that have content on this site. When you access a document or request further information from this site, your information may be shared with the owners of that document or information.